1. Home
  2. CRDF vs KBSX Comparison

CRDF vs KBSX Comparison

Compare CRDF & KBSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Logo FST Corp. Ordinary Shares

KBSX

FST Corp. Ordinary Shares

SELL

Current Price

$1.30

Market Cap

61.6M

ML Signal

SELL

Company Overview

Basic Information
Metric
CRDF
KBSX
Founded
1999
1976
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
61.6M
IPO Year
2012
2024

Fundamental Metrics

Financial Performance
Metric
CRDF
KBSX
Price
$0.87
$1.30
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $5.14
$3.50
AVG Volume (30 Days)
★ 1.0M
3.5K
Earning Date
11-12-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 27.37
N/A
EPS
N/A
★ N/A
Revenue
★ $365,993.00
N/A
Revenue This Year
N/A
$12.74
Revenue Next Year
N/A
$9.70
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 49.61
N/A
52 Week Low
$0.71
$0.81
52 Week High
$3.31
$1.79

Technical Indicators

Market Signals
Indicator
CRDF
KBSX
Relative Strength Index (RSI) N/A 45.62
Support Level N/A $1.14
Resistance Level N/A $1.43
Average True Range (ATR) 0.00 0.09
MACD 0.00 -0.02
Stochastic Oscillator 0.00 36.84

Price Performance

Historical Comparison
CRDF
KBSX

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

About KBSX FST Corp. Ordinary Shares

FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.

Share on Social Networks: